Cost-effectiveness analysis of ribociclib versus palbociclib in the first-line treatment of HR+/HER2− advanced or metastatic breast cancer in Spain

References

• SEOMSociedad Española de Oncología Médica. Las Cifras del Cáncer en España, 2017 [The Cancer figures in Spain, 2017]2017 Available from: https://www.seom.org/seomcms/images/stories/recursos/Las_cifras_del_cancer_en_Esp_2017.pdfAccessed January 16, 2018 Spanish
   Google Scholar
• SEOMSociedad Española de Oncología Médica. [Report of Ribociclib (Kisqali®) as initial endocrine treatment of HR+/HER2− ABC]2018 Available from: https://seom.org/seomcms/images/stories/Informes_SEOM/IEV_Ribociclib.pdfAccessed February 27, 2018 Spanish
   Google Scholar
• FerlayJSteliarova-FoucherELortet-TieulentJCancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012Eur J Cancer20134961374140323485231
   PubMed Web of Science ®Google Scholar
• FerlayJSoerjomataramIDikshitRCancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012Int J Cancer20151365E359E38625220842
   PubMed Web of Science ®Google Scholar
• CardosoFCostaASenkusE3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)Ann Oncol201728123111313328327998
   PubMed Web of Science ®Google Scholar
• GaviláJLopez-TarruellaSSauraCSEOM clinical guidelines in metastatic breast cancer 2015Clin Transl Oncol2015171294695526683474
   PubMed Web of Science ®Google Scholar
• TurnerNCRoJAndréFPalbociclib in Hormone-Receptor-Positive Advanced Breast CancerN Engl J Med2015373320921926030518
   PubMed Web of Science ®Google Scholar
• HortobagyiGNStemmerSMBurrisHARibociclib as First-Line Therapy for HR-Positive, Advanced Breast CancerN Engl J Med2016375181738174827717303
   PubMed Web of Science ®Google Scholar
• GradisharWJAndersonBOBalassanianRBreast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in OncologyJ Natl Compr Canc Netw201816331032029523670
   PubMed Web of Science ®Google Scholar
• PolkAKolmosILKümlerINielsenDLSpecific CDK4/6 inhibition in breast cancer: a systematic review of current clinical evidenceESMO Open201616e00009328848657
   PubMedGoogle Scholar
• HamiltonEInfanteJRTargeting CDK4/6 in patients with cancerCancer Treat Rev20164512913827017286
   PubMed Web of Science ®Google Scholar
• FinnRSMartinMRugoHSPalbociclib and Letrozole in Advanced Breast CancerN Engl J Med Overseas Ed20163752019251936
   PubMed Web of Science ®Google Scholar
• AlbaECiruelosELópezRCost-utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in SpainExpert Rev Pharmacoecon Outcomes Res201313338139123534988
   PubMed Web of Science ®Google Scholar
• SeguíMÁCrespoCCortésJGenomic profile of breast cancer: cost-effectiveness analysis from the Spanish National Healthcare System perspectiveExpert Rev Pharmacoecon Outcomes Res201414688989925213317
   PubMed Web of Science ®Google Scholar
• Ministry of Health, Social Services and Equality [webpage on the Internet]Centro de Información Online de Medicamentos de la Agencia Española de Medicamentos y Productos Sanitarios [Medicines Online Information Center of the Spanish Agency of Medicines and Health Products] Available from: https://www.aemps.gob.es/cima/publico/home.htmlAccessed February 28, 2017
   Google Scholar
• Bot PLUS 20 [homepage on the Internet]Base de datos del Consejo General de Colegios Oficiales de Farmacéuticos [General Council of the Association of Official Pharmacists Database] Available from: https://botplusweb.portalfarma.com/Accessed March 19, 2017 Spanish
   Google Scholar
• Kisqali® (ribociclib) film-coated tablets [summary of product characteristics] Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004213/WC500233997.pdfAccessed February 28, 2017
   Google Scholar
• Ibrance® (palbociclib) hard capsules [summary of product characteristics] Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003853/WC500217196.pdfAccessed February 28, 2018
   Google Scholar
• Femara® (letrozole) film-coated tablets [summary of product characteristics] Available from: https://cima.aemps.es/cima/dochtml/ft/61628/FT_61628.htmlAccessed February 28, 2018
   Google Scholar
• MacalaladARHaoYLinPLTreatment patterns and duration in post-menopausal women with HR+/HER2− metastatic breast cancer in the US: a retrospective chart review in community oncology practices (2004–2010)Curr Med Res Opin201531226327325350226
   PubMed Web of Science ®Google Scholar
• RaphaelJHelouJPritchardKINaimarkDMPalbociclib in hormone receptor positive advanced breast cancer: A cost-utility analysisEur J Cancer20178514615428930692
   PubMed Web of Science ®Google Scholar
• López BastidaJOlivaJAntoñanzasFPropuesta de guía para la evaluación económica aplicada a las tecnologías sanitarias [A proposed guideline for economic evaluation of health technologies]Gac Sanit201024215417019959258
   PubMed Web of Science ®Google Scholar
• HortobagyiGNStemmerSMBurrisHAUpdated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2−), advanced breast cancer (ABC)J Clin Oncol20173515 Suppl1038
   Web of Science ®Google Scholar
• RugoHSFinnRSDierasVAbstract P5-21-03: Palbociclib (PAL) + letrozole (LET) as first-line therapy in estrogen receptor– positive (ER+)/human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC): Efficacy and safety updates with longer follow-up across patient subgroupsCancer Res2018784 SupplementP521-03
   Web of Science ®Google Scholar
• FinnRSCrownJLangIOverall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2– advanced breast cancer (PALOMA-1; TRIO-18J Clin Oncol20173515 Suppl1001
   Web of Science ®Google Scholar
• Committee for Medicinal Products for Human Use. European Medicines AgencyEMA/CHMP/506968/2017 Ribociclib [European Public Assessment Report]2017 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004213/WC500233999.pdfAccessed March 15, 2017
   Google Scholar
• Committee for Medicinal Products for Human UseEuropean Medicines AgencyEMA/652627/2016. Palbociclib [European Public Assessment Report]2016 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/003853/WC500217198.pdfAccessed March 15, 2017
   Google Scholar
• ForsytheAChandiwanaDDolphMTremblayGMonacoM254PMatching-adjusted indirect treatment comparison of ribociclib and palbociclib as first-line treatments for HR+, HER2− ABCAnn Oncol201728Suppl 5254P28426098
   PubMed Web of Science ®Google Scholar
• HettleRSuriGMistryRChandiwanaDLeeACost-Effectiveness of Ribociclib Plus Letrozole Versus Palbociclib Plus Letrozole for Postmenopausal Women with Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2-Negative (HER2−) Advanced/Metastatic Breast Cancer from A UK National Health Service PerspectiveValue Health2017209A433
   Web of Science ®Google Scholar
• DicklerMNBarryWTCirrincioneCTPhase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance)J Clin Oncol201634222602260927138575
   PubMed Web of Science ®Google Scholar
• WeideRFeitenSFriesenhahnVMetastatic breast cancer: prolongation of survival in routine care is restricted to hormone-receptor- and Her2-positive tumorsSpringerplus20143153525279326
   PubMedGoogle Scholar
• GiordanoSHBuzdarAUSmithTLKauSWYangYHortobagyiGNIs breast cancer survival improving?Cancer20041001445214692023
   PubMed Web of Science ®Google Scholar
• TaiPYuEVinh-HungVCserniGVlastosGSurvival of patients with metastatic breast cancer: twenty-year data from two SEER registriesBMC Cancer200446015345027
   PubMed Web of Science ®Google Scholar
• TevaarwerkAJGrayRJSchneiderBPSurvival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 yearsCancer201311961140114823065954
   PubMed Web of Science ®Google Scholar
• LloydANafeesBNarewskaJDewildeSWatkinsJHealth state utilities for metastatic breast cancerBr J Cancer200695668369016967055
   PubMed Web of Science ®Google Scholar
• IslaDGonzález-RojasNNievesDBrosaMFinnernHWTreatment patterns, use of resources, and costs of advanced non-small-cell lung cancer patients in Spain: results from a Delphi panelClin Transl Oncol201113746047121775273
   PubMed Web of Science ®Google Scholar
• eSalud [homepage on the Internet]Base de Datos de Costes Sanitarios Españoles [Spanish Health Costs Database]Oblikue Consulting, S.L; 2007 Available from: http://www.oblikue.com/bddcostes/Accessed June 21, 2017
   Google Scholar
• Conjunto Mínimo Básico de Datos al alta hospitalaria [Basic minimum dataset of hospital discharge] [homepage on the Internet]Ministerio de Sanidad, Servicios Sociales e Igualdad [Ministry of Health, Social Services and Equality] Available from: http://pestadistico.inteligenciadegestion.msssi.esAccessed June 22, 2017
   Google Scholar
• FinnRSMartinMRugoHSPalbociclib and Letrozole in Advanced Breast CancerN Engl J Med2016375201925193627959613
   PubMed Web of Science ®Google Scholar
• LiNduEXChuLReal-world palbociclib dosing patterns and implications for drug costs in the treatment of HR+/HER2- metastatic breast cancerExpert Opin Pharmacother201718121167117828699804
   PubMed Web of Science ®Google Scholar
• BriggsAHHandling uncertainty in cost-effectiveness modelsPharmacoeconomics200017547950010977389
   PubMed Web of Science ®Google Scholar
• SacristánJAOlivaJdel LlanoJPrietoLPintoJL¿Qué es una tecnología sanitaria eficiente en España? [What is an efficient health technology in Spain?]Gac Sanit200216433434312113733
   PubMedGoogle Scholar
• Ortega EslavaAMarín GilRFraga FuentesMDLópez-BrizEPuigventós LatorreFGuía de Evaluación Económica e Impacto Presu-puestario En Los Informes de Evaluación de Medicamentos [Economic Evaluation and Budgetary Impact Guidelines for Assessment Reports on Medicinal Products]MadridSociedad Española de Farmacia Hospitalaria (SEFH)2016 Available from: https://gruposdetrabajo.sefh.es/genesis/genesis/Documents/GUIA_EE_IP_GENESIS-SEFH_19_01_2017.pdfAccessed May 22, 2017
   Google Scholar
• Vallejo-TorresLGarcia-LorenzoBGarcia-PérezLLinertováRSerrano-AguilarPDisponibilidad a Pagar de La Sociedad Española Por Un Año de Vida Ajustado Por Calidad [Spanish Society Willingness to- Pay for One Quality-Adjusted Life Year]MadridMinisterio de Sanidad, Servicios Sociales e Igualdad. Servicio de Evaluación del Servicio Canario de la Salud2017 Available from: http://www.redets.mscbs.gob.es/documentos/SESCS_2016_DAP_AVAC.pdfAccessed May 22, 2017
   Google Scholar
• RavdinPMCroninKAHowladerNThe decrease in breast-cancer incidence in 2003 in the United StatesN Engl J Med2007356161670167417442911
   PubMed Web of Science ®Google Scholar
• SánchezMJPayerTde AngelisRCancer incidence and mortality in Spain: estimates and projections for the period 1981–2012Ann Oncol201021Suppl 3iii30iii3620427358
   PubMed Web of Science ®Google Scholar
• Fernández de Larrea-BazNAlvarez-MartínEMorant-GinestarCBurden of disease due to cancer in SpainBMC Public Health2009914219183440
   PubMed Web of Science ®Google Scholar
• Matter-WalstraKRuhstallerTKlingbielDSchwenkglenksMDedesKJPalbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK)Breast Cancer Res Treat20161581515727277747
   PubMed Web of Science ®Google Scholar
• BhattacharyaKYangYA Cost-Effectiveness Analysis of Palbociclib and other Aromatase Inhibitors for Treatment of Advanced Breast CancerValue Health2016193A150
   Web of Science ®Google Scholar
• SimonsWRJonesDBuzdarACost-effectiveness of anastrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancerClin Ther200325112972298714693319
   PubMed Web of Science ®Google Scholar
• CressmanSBrowmanGPHochJSKovacicLPeacockSJA Time-Trend Economic Analysis of Cancer Drug TrialsOncologist201520772973626032135
   PubMed Web of Science ®Google Scholar
• DranitsarisGVermaSTrudeauMCost utility analysis of first-line hormonal therapy in advanced breast cancer: comparison of two aromatase inhibitors to tamoxifenAm J Clin Oncol200326328929612796603
   PubMed Web of Science ®Google Scholar
• MarchettiMCaruggiMColomboGCost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health ServiceClin Ther20042691546156115531017
   PubMed Web of Science ®Google Scholar
• dasRCopeSOuwensMTurnerPHowlettMEconomic evaluation of fulvestrant 500 mg versus generic nonsteroidal aromatase inhibitors in patients with advanced breast cancer in the United KingdomClin Ther201335324626023453402
   PubMed Web of Science ®Google Scholar
• NerichVBazanFCompagnatFFirst-line bevacizumab plus taxane-based chemotherapy for metastatic breast cancer: cost-minimisation analysisAnticancer Res20123283547355222843944
   PubMed Web of Science ®Google Scholar
• NICENational Institute for Health and Care Excellence [webpage on the Internet]Fulvestrant for the Treatment of Locally Advanced or Metastatic Breast Cancer2011 Available from: https://www.nice.org.uk/guidance/ta239Accessed March 15, 2017
   Google Scholar
• NICENational Institute for Health and Care Excellence [webpage on the Internet]Everolimus with Exemestane for Treating Advanced Breast Cancer After Endocrine Therapy2013 Available from: https://www.nice.org.uk/guidance/TA421Accessed March 15, 2017
   Google Scholar
• WoodsBSiderisEPalmerSLatimerNSoaresMNICE: DSU Technical Support Document 19. Partitioned Survival Analysis for Decision Modelling in Health Care: A Critical ReviewLondonNICE Decision Support Unit2017 Available from: http://scharr.dept.shef.ac.uk/nicedsu/wp-content/uploads/sites/7/2017/06/Partitioned-Survival-Analysis-final-report.pdfAccessed September 10, 2018
   Google Scholar
• SignorovitchJESikiricaVErderMHMatching-adjusted indirect comparisons: a new tool for timely comparative effectiveness researchValue Health201215694094722999145
   PubMed Web of Science ®Google Scholar